|
|
|
|
In the setting of early diagnosis and consequent treatment, natalizumab-associated PML can be well managed in some cases. This situation differs from the course of PML in other conditions, e.g., after the application of depleting monoclonal antibodies, in which irreversible cellular effects are associated with very high mortality. |
|